Background: The World Health Organization (WHO) lists pregnant women as the highest priority group for seasonal influenza vaccination; however, influenza vaccine uptake consistently remains suboptimal. Poor uptake has partly been attributed to safety concerns particularly during early pregnancy.
EFFECT OF ENOXAPARIN, A LOW MOLECULAR WEIGHT HEPARIN, ON UTERO-PLACENTAL DOPPLER WAVEFORMS AND FETAL GROWTH VELOCITY IN A HIGH RISK POPULATION; SECONDARY ANALYSES OF THE EPPI TRIAL
The EPPI trial, a multi-centre randomised controlled trial of enoxaparin for the prevention of preeclampsia and fetal growth restriction in women at high risk, did not demonstrate any benefit of enoxaparin in addition to standard high risk care (including aspirin) on the incidence of these conditions. a There may be smaller effects undetermined in a trial of this size but significant on utero-placental function and fetal growth velocity.
Methods: Secondary analysis of EPPI trial data comparing uterine and umbilical artery Doppler waveform at 20 weeks gestation and fetal growth velocity (third trimester change in abdominal circumference (AC) z score) in women randomised to treatment with or without enoxaparin.
Results: Enoxaparin has no effect on uterine artery mean pulsatility index (PI) (1.20 vs 1.16, p=0.5, least squares mean (LSM) difference 0.05, 95%CI -0.11 to 0.23), proportion of women with PI>95 th centile (8/54 vs 6/52, adjOR 1.32, 95%CI 0.42-4.13) or proportion of women with diastolic notching (unilateral 7/42 vs 4/37 and bilateral 8/42 vs 6/37, adjOR for increasing severity 1.37, 95%CI 0.52-3.56). Enoxaparin also has no effect on mean umbilical artery PI (1.26 vs 1.26 p=0.6, LSM difference 0.02, 95%CI -0.06 to 0.11) or change in AC z scores, LSM 0.016 (95% CI -0.04 to 0.07) vs 0.005 (95%CI -0.05 to 0.05) with LSM difference of the two groups = 0.01 (p=0.67).
Conclusions: The addition of enoxaparin to standard high risk care has no effect on Doppler measures of utero-placental function or fetal growth velocity in the third trimester.
a Groom et al AJOG 2017;216:296.e1-14. For most women (84%) the risks of CS had been explained by maternity care providers but ACS use had only been discussed with five and offered to two. After provision of information regarding ACS and planned CS, 11 (17%) women identified they would definitely/probably accept ACS in their current pregnancy, 28 (44%) were unsure and 23 (37%) identified maybe or not at all. Lack of information about risks/benefits was the most important factor determining their decision. With regards to participation in a randomised placebo-controlled trial; 15 (25%) would definitely/probably, 29 (48%) maybe/unsure and 17 (27%) not all. The outcomes of most importance related to short-and longterm respiratory morbidity for their child rather than breastfeeding success and academic performance. Conclusions: Women have varied opinions on the use of ACS prior to planned CS and involvement in a RCT. This study highlights the need for high quality evidence to allow women to make informed decisions.
CONSUMER ATTITUDES TO ANTENATAL CORTICOSTEROID (ACS) THERAPY PRIOR TO PLANNED CAESAREAN SECTION (CS) FROM 35 WEEKS GESTATION: A FEASIBILITY STUDY

